Show simple item record

dc.contributor.authorSwanton, Tessa; orcid: 0000-0003-1776-080X
dc.contributor.authorBeswick, James A; orcid: 0000-0002-3985-9141
dc.contributor.authorHammadi, Halah
dc.contributor.authorMorris, Lucy
dc.contributor.authorWilliams, Daniel
dc.contributor.authorde Cesco, Stephane
dc.contributor.authorEl-Sharkawy, Lina
dc.contributor.authorYu, Shi
dc.contributor.authorGreen, Jack
dc.contributor.authorDavis, John B
dc.contributor.authorLawrence, Catherine B
dc.contributor.authorBrough, David; orcid: 0000-0002-2250-2381
dc.contributor.authorFreeman, Sally
dc.date.accessioned2021-07-09T01:08:04Z
dc.date.available2021-07-09T01:08:04Z
dc.date.issued2020-10-12
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625196/article.pdf?sequence=2
dc.identifier.citationChemical science, volume 11, issue 43, page 11720-11728
dc.identifier.urihttp://hdl.handle.net/10034/625196
dc.descriptionFrom Europe PMC via Jisc Publications Router
dc.descriptionHistory: ppub 2020-10-01, epub 2020-10-12
dc.descriptionPublication status: Published
dc.descriptionFunder: Medical Research Council; Grant(s): MR/N029992/1, MC_PC_17172, MR/T016515/1
dc.descriptionFunder: Alzheimer's Society; Grant(s): AS-PhD-16-002, 10
dc.descriptionFunder: Alzheimers Research UK; Grant(s): ARUK-2015DDI-OX
dc.description.abstractThe NLRP3 inflammasome regulates production of the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18, and contributes to inflammation exacerbating disease. Fenamate non-steroidal anti-inflammatory drugs (NSAIDs) were recently described as NLRP3 inflammasome inhibitors <i>via</i> chloride channel inhibition. Fenamate NSAIDs inhibit cyclooxygenase (COX) enzymes, limiting their potential as therapeutics for NLRP3-associated diseases due to established side effects. The aim here was to develop properties of the fenamates that inhibit NLRP3, and at the same time to reduce COX inhibition. We synthesised a library of analogues, with feedback from <i>in silico</i> COX docking potential, and IL-1β release inhibitory activity. Through iterative screening and rational chemical design, we established a collection of chloride channel inhibiting active lead molecules with potent activity at the canonical NLRP3 inflammasome and no activity at COX enzymes, but only in response to stimuli that activated NLRP3 by a K<sup>+</sup> efflux-dependent mechanism. This study identifies a model for the isolation and removal of unwanted off-target effects, with the enhancement of desired activity, and establishes a new chemical motif for the further development of NLRP3 inflammasome inhibitors.
dc.languageeng
dc.rightsLicence for this article: cc by
dc.sourceissn: 2041-6520
dc.sourceessn: 2041-6539
dc.sourcenlmid: 101545951
dc.titleSelective inhibition of the K<sup>+</sup> efflux sensitive NLRP3 pathway by Cl<sup>-</sup> channel modulation.
dc.typearticle
dc.date.updated2021-07-09T01:08:04Z


Files in this item

Thumbnail
Name:
article.pdf
Size:
1018.Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record